Inotuzumab Ozogamicin (Genetical Recombination)



Inotuzumab Ozogamicin is an antibody-drug-conjugate (molecular weight: ca. 159,000) consisting of Ozogamicin (methyl (1R, 4Z, 8S, 13E)-8-(4,6-dideoxy-4-{[(4-S-{4-[(6-deoxy-3-O-methyl-α- L-mannopyranosyl)oxy]-3-iodo-5,6-dimethoxy-2-methylbenzoyl}-4-sulfanyl-β- D-ribo-hexopyranosyl)oxy]amino}-2-O-[2,4-dideoxy-4-(N-ethylacetamido)- 3-O-methyl-α- L-threo-pentopyranosyl]- β- D-glucopyranosyloxy)-13-[2-({4-[2-(1-{[4-(4-amino-4-oxobutyl)oxy]phenyl}ethylidene)hydrazinyl]-2-methyl-4-oxobutan-2-yl}disulfanyl)ethylidene]-1-hydroxy-11-oxobicyclo[7.3.1]trideca-4,9-diene-2,6-diyn-10-yl}carbamate (C₇₃H₉₇IN₆O₂₅S₃; molecular weight: 1,681.68)) attached to an average of 6 Lys residues of a recombinant monoclonal antibody (molecular weight: ca. 149,000). The monoclonal antibody moiety is a humanized monoclonal antibody composed of complementarity-determining regions derived from mouse anti-human CD22 monoclonal antibody and framework regions and constant regions from human IgG4 and produced in Chinese hamster ovary cells. The protein moiety is a glycoprotein composed of 2 H-chains (γ4-chain) consisting of 448 amino acid residues each and 2 L-chains (κ-chain) consisting of 219 amino acid residues each.

[635715-01-4]